Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma

This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride work in treating teenagers or young adults with osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, or soft tissue sarcoma that has come back (recurrent) or does not respond to treatment (refractory). Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Pediatrics, Sarcoma
Phase II
Both
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
Filgrastim (GCSF), Gemcitabine, Nab-Paclitaxel, Pegfilgrastim
Borinstein, Scott
National
Vanderbilt University
05-03-2019
Treatment
VICCPED18142
NCT02945800

Eligibility

3 Years
BOTH
NO
Inclusion Criteria:

Have had a histologic diagnosis of osteosarcoma, Ewing sarcoma, or rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma either at diagnosis or relapse * Patients must have experienced relapse after front-line therapy, or have had documented disease progression during front-line therapy

All patients must have measurable disease that can be assessed using RECIST 1.1 criteria, which is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or CT scan that can be accurately measured with the longest diameter of 10 mm in at least one dimension; for this phase II trial, patients with disease limited to bone or marrow metastases are NOT eligible

Patients must have relapsed or refractory cancers for which there is no known curative option

Prior therapy: there is no limit to the number of prior therapies provided all eligibility criteria are met; however, patients must have recovered from the acute toxic effects of all prior treatment * Patients must not have received prior therapy with either gemcitabine or nab-paclitaxel * Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of protocol therapy on this study * Hematopoietic growth factors: 7 days must have elapsed from the start of protocol therapy since the completion of therapy with filgrastim, and 14 days must have elapsed from the start of protocol therapy after receiving pegfilgrastim * Biologic (anti-neoplastic agent): 7 days must have elapsed from the start of protocol therapy since the completion of therapy with a biologic agent * Monoclonal antibodies: 3 half-lives must have elapsed from the start of protocol therapy since prior therapy that included a monoclonal antibody * Radiotherapy: 2 weeks must have elapsed from the start of protocol therapy since local palliative radiation therapy (XRT) (small port); 3 months must have elapsed if 50% radiation of pelvis; 6 weeks must have elapsed if other substantial bone marrow irradiation was given * Stem cell transplant or rescue: no evidence of active graft versus (vs.) host disease and 2 months must have elapsed from the start of protocol therapy since transplant

Karnofsky performance score must be >= 60

Absolute neutrophil count >= 1,000/mcL

Platelets >= 100,000/mcL

Total bilirubin within normal institutional limits

Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =
Serum creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

Neuropathy: patients must have =
Central nervous system (CNS) metastases: patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months from the start of protocol therapy

Contraception: women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of gemcitabine and nab-paclitaxel administration

Consent: patients must have the ability to understand and the willingness to sign a written informed consent or assent document



Exclusion Criteria:

Patients who are receiving any other investigational agents are ineligible

Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer

Patients with a history of allergic reactions attributed to docetaxel or paclitaxel are ineligible

Concomitant medications: the following medicines should be avoided on this study: * Inhibitors: ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir * Inducers: rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine * Patients receiving any of the above medications are ineligible

Patients are ineligible if they have uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations that would limit compliance with study requirements

Pregnancy and breastfeeding: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study

Human immunodeficiency virus (HIV) infection: HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: